By Mill Chart
Last update: Oct 10, 2023
PFIZER INC (NYSE:PFE) is a hidden gem unveiled by our stock screening tool, featuring a promising dividend outlook alongside solid fundamentals. NYSE:PFE demonstrates decent financial health and profitability while ensuring a sustainable dividend. Let's break it down further.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:PFE was assigned a score of 8 for dividend:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 5 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:PFE, the assigned 8 is a significant indicator of profitability:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
For an up to date full fundamental analysis you can check the fundamental report of PFE
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
PFIZER INC
NYSE:PFE (4/29/2024, 10:29:08 AM)
25.745
+0.35 (+1.36%)
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
These stocks aren't bargains.
With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip.
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
You'll get dividends and more with these great stocks.
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.